WHO Adds Semaglutide to Essential Medicines List, Urges Cheaper Generics

What's Happening?

The World Health Organization (WHO) has added semaglutide, the active ingredient in Ozempic and Wegovy, to its list of essential medicines. This decision aims to improve the affordability and accessibility of semaglutide and other GLP-1 drugs, which have significantly impacted the treatment of type 2 diabetes and obesity. Despite their effectiveness, these drugs are expensive and often not covered by insurance. The WHO's list, first released in 1977, serves as a global guide for countries to prioritize medications that can broadly improve public health. Semaglutide, along with dulaglutide and liraglutide, has been recognized for its ability to regulate hunger cues and metabolism, making it a game-changer in diabetes and obesity treatment.

Why It's Important?

The inclusion of semaglutide in the WHO's essential medicines list highlights the drug's potential to transform diabetes and obesity treatment globally. These conditions are major public health concerns, as they can reduce lifespan and increase the risk of chronic diseases like cancer. GLP-1 drugs have shown effectiveness in controlling blood sugar and aiding weight loss, which could lead to a decrease in obesity rates. However, their high cost and limited insurance coverage make them inaccessible to many. The WHO's move could encourage the development of cheaper generic versions and improve access, potentially benefiting millions worldwide.

What's Next?

Canada is expected to approve generic versions of semaglutide as early as next year, while the U.S. may not see generics until 2031. The WHO's decision could prompt public health officials to prioritize access to GLP-1 drugs for those most likely to benefit, and encourage multisectoral cooperation to reduce costs. This could lead to increased availability through primary care and more equitable access to these essential medicines.

Beyond the Headlines

The WHO's action underscores the need for a coherent health system response to ensure equitable access to essential medicines. This requires strong political will and people-centered programs that leave no one behind. The move could also stimulate discussions on the ethical implications of drug pricing and access, particularly for life-changing medications.